Succinyl-Coenzyme A (sodium salt)
(Synonyms: 琥珀酰辅酶A钠盐,Succinyl-CoA) 目录号 : GC44961An intermediate in the citric acid cycle
Cas No.:108347-97-3
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Succinyl-coenzyme A (succinyl-CoA) is an intermediate in the citric acid cycle.[1] It is converted to succinate, which is a metabolic intermediate with various biological activities. Succinyl-CoA is required, with glycine, to form δ-aminolevulinic acid in the first step of porphyrin and heme synthesis.[2] Succinyl-CoA deficiency, caused by vitamin B12 deficiency can disrupt heme and energy production, leading to neuromotor dysfunction.[3]
琥珀酰辅酶A(琥珀酰-CoA)是三羧酸循环中的中间产物[1]。它转化为丙酸,后者是具有各种生物活性的代谢中间体。琥珀酰-CoA与甘氨酸一起参与卟吩和血红素合成中的第一步反应,形成δ-氨基腺嘌呤酸[2]。由于维生素B12缺乏引起的琥珀酰-CoA缺乏可能会破坏血红素和能量生产,导致神经运动障碍[3]。
Reference:
[1]. Meister, A. ACYL phosphates as enzyme-bound intermediates in the biosynthesis of glutamine, glutathione, succinyl, coenzyme A, and cabamyl phosphate. Trans. N. Y. Acad. Sci. 30(8), 1157-1180 (1968).
[2]. Bonkovsky, H.L., Guo, J.-T., Hou, W., et al. Porphyrin and heme metabolism and the porphyrias. Compr Physiol 3(1), 365-401 (2013).
[3]. Bicakci, Z. Growth retardation, general hypotonia, and loss of acquired neuromotor skills in the infants of mothers with cobalamin deficiency and the possible role of succinyl-CoA and glycine in the pathogenesis. Medicine (Baltimore) 94(9), e584 (2015).
Cas No. | 108347-97-3 | SDF | |
别名 | 琥珀酰辅酶A钠盐,Succinyl-CoA | ||
化学名 | S-(hydrogen butanedioate), coenzyme A, sodium salt | ||
Canonical SMILES | O[C@H]1[C@H](N2C=NC3=C2N=CN=C3N)O[C@H](COP(OP(OCC(C)(C)[C@@H](O)C(NCCC(NCCSC(CCC(O)=O)=O)=O)=O)(O)=O)(O)=O)[C@H]1OP(O)(O)=O.[Na] | ||
分子式 | C25H40N7O19P3S•XNa | 分子量 | 867.6 |
溶解度 | 10mg/mL in PBS, pH 7.2 | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.1526 mL | 5.763 mL | 11.526 mL |
5 mM | 0.2305 mL | 1.1526 mL | 2.3052 mL |
10 mM | 0.1153 mL | 0.5763 mL | 1.1526 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。